Invetech has named Alex Zrolka vice president of business development for the company’s North American life sciences division, the firm said this week.
Zrolka previously worked in marketing management, business development, and sales for Biotech Envoy, Genicon Sciences, Qiagen, Bio-Rad Laboratories, and DNAStar.
OVP Venture Partners has tapped Carl Weissman to join the company. He will focus on investing in digital biology and “the convergence of IT, nanotechnology, and biotechnology,” the company said.
Weissman is currently CEO and president of Seattle-based Accelerator, a venture capital investment vehicle. OVP said Weissman will maintain his post at Accelerator while assuming his partner duties at OVP.
Erik Wallden has joined the board of directors of VisEn Medical, a developer of fluorescence in vivo imaging technology. Wallden was most recently president and CEO of Biacore International, which was acquired by GE Healthcare last September.
Before joining Biacore in 2004, Wallden was president and CEO of Pyrosequencing. He also held management positions at PerSeptive Biosystems (now Applied Biosystems), Pharmacia Biosensor (now Biacore), and Pharmacia Biotech (now GE Healthcare Life Sciences).
Wallden is currently on the industrial supervisory board of Healthinvest Partners and director of Proxeon and Bergekullen Fastighets.